Benign Hypertrophy of prostate. Hypertrophy (benign)) of prostate
Conditions
Interventions
Intervention 1: The Seidlitzia rosmarinus group3 (n=62): Seidlitzia rosmarinus 3 gr/day plus perazisin at 1 mg daily for two months. Intervention 2: The Urtica diociea group3 (n=62): Urtica diociea
Treatment - Drugs
The Seidlitzia rosmarinus group3 (n=62): Seidlitzia rosmarinus 3 gr/day plus perazisin at 1 mg daily for two months
The Urtica diociea group3 (n=62): Urtica diociea 3 gr/day plus perazisin at 1 mg daily for two months
The Seidlitzia rosmarinus group5 (n=62): Seidlitzia rosmarinus 5 gr/day plus perazisin at 1 mg daily for two months
The Equisetum arvense group7 (n=62): Equisetum arvense 7 gr/day plus perazisin at 1 mg daily for two months
The Urtica diociea group5 (n=62): Urtica diociea 5 gr/day plus perazisin at 1 mg daily for two months
The Urtica diociea group7 (n=62): Urtica diociea 7 gr/day plus perazisin at 1 mg daily for two months
The Equisetum arvense group3 (n=62): Equisetum arvense3 gr/day plus perazisin at 1 mg daily for two months
The Equisetum arvense group5 (n=62): Equisetum arvense 5 gr/day plus perazisin at 1 mg daily for two months
The Seidlitzia rosmarinus group7(n=62): Seidlitzia rosmarinus 7 gr/day plus perazisin at 1 mg daily for two months
Sponsors
Razi Herbal Medicine Research Center of Lorestan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
49 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Age of 49 and above; New BPH diagnosed cases; To have storage or voiding symptoms; AUA score of 7 and above; Urine Bacterial count less than 100000/ml; Serum ceartinine less than 1.5 mg/dl; PSA less than 4 n/ml Exclusion criteria: To have history of prostate cancer; To have prostatitis; Neurogenic blader cases; To have Diabetes mellitus; To have Nephropathy; To have CHF; To have Renal failure; To have more than two antihypertensive drugs; To have non prescriptive herbal drugs;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Storage or voiding clinical symptoms. Timepoint: Before and 2 months after the intervention. Method of measurement: AUA Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum PSA. Timepoint: Before and 2 months after the intervention. Method of measurement: Blood laboratory test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Hosseinabadi
Lorestan University of Medical Sciences, School of Nursing & Midwifery
Outcome results
None listed